PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50
- 39 Downloads
Anaplastic thyroid carcinoma (ATC) is an aggressive malignant tumor composed of undifferentiated thyroid follicular cells. Pathological diagnosis of ATC can be challenging as the tumor may show morphological overlap with other neoplasms with anaplastic morphology. Immunohistochemical demonstration of thyroid origin facilitates the diagnosis of ATC. Previous studies using the polyclonal anti-PAX8 antibody 10336-1-AP suggested that PAX8 was the most sensitive marker, expressed in up to 80% of ATC. According to a 2018 NordiQC report, the monoclonal anti-PAX8 antibody MRQ-50 has become the most commonly used anti-PAX8 antibody worldwide. However, validation of this antibody in ATC is lacking. In this study, we recruited 182 ATC cases from seven institutions. Pathology slides were subjected to histology review. PAX8 immunohistochemistry using the MRQ-50 antibody was performed in whole tissue slides (n = 147) or tissue microarray sections (n = 35). We found PAX8 expression in 54.4% of the cases, which was significantly lower than those reported in prior studies with the polyclonal antibody. PAX8 expression was positively correlated with the presence of an epithelial pattern (63.6% vs 37.5%, p = 0.0008) and a coexisting differentiated thyroid carcinoma component (71.6% vs 44.3%, p = 0.0004), but was not associated with age, gender, specimen type, or presence of giant cell and sarcomatoid patterns. In conclusion, we demonstrated PAX8 expression using the monoclonal antibody MRQ-50 in only half of the cases in a large ATC series. Pathologists should be aware that PAX8 expression in ATC is less than those reported in early studies to avoid misdiagnosis.
KeywordsPaired box gene 8 (PAX8) Anaplastic thyroid carcinoma (ATC) Undifferentiated thyroid carcinoma Immunohistochemistry MRQ-50
A. Bychkov and J. Hang designed the study. W. Lai, J. Hang, C. Liu, Y. Bai, Z. Liu, H. Gu, S. Hong, J. Pyo, C. Jung, and A. Bychkov reviewed the slides and collected the data. W. Lai and J. Hang analyzed the data and performed the study. W. Lai, J. Hang, and A. Bychkov wrote the paper. K. Kakudo supervised the study and provided critical revision.
This study was supported by the research grant from Taipei Veterans General Hospital, Taipei, Taiwan (Grant No.: V108B-011).
Compliance with ethical standards
This study was approved by the institutional review boards of the participating centers.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, Basolo F, Vitti P, Elisei R (2017) Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol 13:644–660. https://doi.org/10.1038/nrendo.2017.76 CrossRefPubMedGoogle Scholar
- 9.Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS (2011) A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 35:816–826. https://doi.org/10.1097/PAS.0b013e318216c112 CrossRefPubMedGoogle Scholar
- 12.Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F (2011) N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Pathol 25:231–236. https://doi.org/10.1038/modpathol.2011.162 CrossRefPubMedGoogle Scholar
- 14.Kuhn E, Ragazzi M, Ciarrocchi A, Torricelli F, de Biase D, Zanetti E, Bisagni A, Corrado S, Uccella S, La Rosa S, Bongiovanni M, Losito S, Piana S (2019) Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study. Mod Pathol 32:787–798. https://doi.org/10.1038/s41379-018-0199-z CrossRefPubMedGoogle Scholar
- 16.Lloyd RV, Osamura RY, Klöppel G, Rosai J (2017) WHO classification of tumours of endocrine organs, 4th edn. International Agency for Research on Cancer, LyonGoogle Scholar
- 19.Nikiforov YE, Biddinger PW, Thompson LD (2012) Diagnostic pathology and molecular genetics of the thyroid: a comprehensive guide for practicing thyroid pathology. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar